TP53 and neoplasm: Approximately 80% of the variants identified in the p53 gene are point mutations situated in a few hotspot codons and resulting in the loss of the tumor suppressor function and a dominant-negative effect of p53 activity, along with a gain of new oncogenic functions leading to therapeutic resistance (Giacomelli et al. 2018; Zhou et al. 2019).